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Autoreactive CD4
+ T lymphocytes play a vital role in the pathogenesis of multiple sclerosis and its animal model, experimental
autoimmune encephalomyelitis. Since the discovery of T helper 17 cells, there is an ongoing debate whether T helper 1, T helper
17 or both subtypes of T lymphocytes are important for the initiation of autoimmune neuroinﬂammation. We examined periph-
eral blood CD4
+ cells from patients with active and stable relapsing–remitting multiple sclerosis, and used mice with conditional
deletion or over-expression of the transforming growth factor-b inhibitor Smad7, to delineate the role of Smad7 in T cell
differentiation and autoimmune neuroinﬂammation. We found that Smad7 is up-regulated in peripheral CD4
+ cells from patients
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scription factor deﬁning T helper 1 responses. Concordantly, mice with transgenic over-expression of Smad7 in T cells developed
an enhanced disease course during experimental autoimmune encephalomyelitis, accompanied by elevated inﬁltration of inﬂam-
matory cells and T helper 1 responses in the central nervous system. On the contrary, mice with a T cell-speciﬁc deletion of
Smad7 had reduced disease and central nervous system inﬂammation. Lack of Smad7 in T cells blunted T cell proliferation and T
helper 1 responses in the periphery but left T helper 17 responses unaltered. Furthermore, frequencies of regulatory T cells were
increased in the central nervous system of mice with a T cell-speciﬁc deletion and reduced in mice with a T cell-speciﬁc
over-expression of Smad7. Downstream effects of transforming growth factor-b on in vitro differentiation of naı ¨ve T cells to
T helper 1, T helper 17 and regulatory T cell phenotypes were enhanced in T cells lacking Smad7. Finally, Smad7 was induced
during T helper 1 differentiation and inhibited during T helper 17 differentiation. Taken together, the level of Smad7 in T cells
determines T helper 1 polarization and regulates inﬂammatory cellular responses. Since a Smad7 deletion in T cells leads to
immunosuppression, Smad7 may be a potential new therapeutic target in multiple sclerosis.
Keywords: EAE; multiple sclerosis; immune regulation; T cell responses; T helper 1
Abbreviations: EAE = experimental autoimmune encephalomyelitis; ELISA = enzyme-linked immunosorbent assay; IFN-g = gamma
interferon; IL = interleukin; MOG = myelin oligodendrocyte glycoprotein; qRT-PCR = quantitative real-time polymerase chain
reaction; RPMI = Roswell Park Memorial Institute; TGF-b = transforming growth factor-b; TGF-bR = transforming growth factor-b
receptor; Th = T helper
Introduction
Multiple sclerosis is a chronic inﬂammatory and degenerative dis-
ease of the central nervous system (CNS) believed to be of auto-
immune origin (Compston and Coles, 2008). In majority of
patients, multiple sclerosis initially presents as a relapsing–remitting
disease with acute inﬂammatory attacks against CNS tissue, fol-
lowed by complete recovery. Although the exact aetiology of mul-
tiple sclerosis remains unknown, it is widely accepted that
the activation of myelin-speciﬁc CD4
+ T cells is a central step in
the initiation of neuroinﬂammation (Sospedra and Martin, 2005).
The strongest genetic risk factors for multiple sclerosis were found
in the HLA-DRA, interleukin (IL)-2R and IL-7R genes (Haﬂer
et al., 2007), emphasizing the importance of CD4
+ T cells.
The animal model of multiple sclerosis, experimental autoim-
mune encephalomyelitis (EAE), is induced by immunization with
myelin components or by adoptive transfer of encephalitogenic
CD4
+ T cells into naı ¨ve animals (Zamvil and Steinman, 1990).
Because of similarities to the EAE model, the fact that administra-
tion of the quintessential T helper (Th) 1 cytokine gamma inter-
feron (IFN-g) worsened multiple sclerosis (Panitch et al., 1987),
and the typical cellular composition of brain- and cerebrospinal
ﬂuid-inﬁltrating cells, multiple sclerosis for a long time was con-
sidered to be a Th1-mediated disease (Sospedra and Martin,
2005). However, since the characterization of the Th17 phenotype
and its pathogenic role in EAE (Cua et al., 2003; Langrish et al.,
2005; Chen et al., 2006) and multiple sclerosis (Kebir et al., 2007),
there is ongoing debate whether Th1, Th17, or both subtypes of T
lymphocytes are important for the initiation of autoimmune CNS
inﬂammation (McFarland and Martin, 2007; Steinman, 2008).
Transforming growth factor (TGF)-b1 is a master regulator of
immune responses, initiating signalling events in target cells that
have vital and non-redundant regulatory functions (Letterio and
Roberts, 1998; Li et al., 2006a). While TGF-b blocks the differen-
tiation of Th1 and Th2 cells by inhibiting T-bet and GATA-3
(Gorelik et al., 2000, 2002), respectively, it promotes the genera-
tion of inducible regulatory T cells by up-regulating Foxp3 (Chen
et al., 2003). Under inﬂammatory conditions, in particular in the
presence of IL-6, TGF-b supports the differentiation of Th17 cells,
which are implicated in autoimmune diseases (Bettelli et al., 2006;
Mangan et al., 2006; Veldhoen et al., 2006). Despite rapid pro-
gress in elucidating the cytokine networks involved in T cell dif-
ferentiation, molecular mechanisms mediating context-dependent
cellular responses after activation of the transforming growth
factor-b receptor (TGF-bR) are only partly understood.
The Smad family of proteins mediates signalling from the TGFbR
to the nucleus (Shi and Massague, 2003). Smad7, which is
induced by TGFb itself, forms part of an inhibitory feedback-loop
by binding to the intracellular domain of the activated TGFbRI
(Hayashi et al., 1997; Nakao et al., 1997). It prevents the phos-
phorylation of Smad proteins, associates with ubiquitin ligases
involved in TGF-bR-degradation and acts as a transcriptional
repressor inhibiting Smad-dependent promoter activation
(Schmierer and Hill, 2007). Since Smad7 is responsible for the
ﬁne-tuning of TGF-b signals (Itoh and ten Dijke, 2007), an aber-
rant expression of Smad7 might disrupt the balanced activity of
TGF-b under physiological and pathophysiological conditions.
Here, we sought to address the role of Smad7 in the pathogen-
esis of autoimmune neuroinﬂammation by examining peripheral
CD4
+ cells from patients with multiple sclerosis and mice with
either a T cell-speciﬁc deletion or over-expression of Smad7. We
found Smad7 to be elevated in CD4
+ cells from patients with
multiple sclerosis during relapses but not remission, and a signiﬁ-
cant correlation between the expression of Smad7 and T-bet. Mice
with Smad7 over-expression showed enhanced, and mice with a
lack of Smad7 in T cells reduced EAE and Th1 responses. In vitro,
Th17 differentiation was reciprocally regulated compared to Th1
differentiation, indicating that Smad7 controls the balance
between Th1 and Th17 responses. We conclude that both initia-
tion of EAE and relapses in multiple sclerosis are mainly driven by a
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CNS autoimmunity.
Materials and methods
Generation of Smad7
ﬂ/ﬂ mice
The Smad7
ﬂ/ﬂ mouse strain was generated using standard gene
targeting techniques (Torres and Kuhn, 1997). In brief, a
Smad7-targeting vector ﬂanking promoter region and exon I (–983
to +2415) by loxP sites was generated by inserting the short arm of
homology, the promoter region with exon I and the long arm of
homology into the targeting vector pRapidFlirt, containing the loxP
sites, the frt-ﬂanked neomycin resistance gene, and the
HSV-thymidine kinase gene as negative selection markers
(Hovelmeyer et al., 2007). All DNA fragments were ampliﬁed from
the C57BL/6J-derived BAC-clone RP24-263P17 (BACPAC Resources,
Children’s Hospital Oakland Research Institute) and veriﬁed by
sequencing. The targeting vector was linearized and electroporated
into Bruce-4 embryonic stem cells of C57BL/6 origin (Kontgen et al.,
1993). Recombinant embryonic stem cells were identiﬁed by Southern
blot analysis (primers for probe: sen 50-ATGGGAGAA
GAGAGCAGGATTG-30, ase 50-AAAAGAAAGATAGCCCCGAAGC-30)
and were veriﬁed using in vitro deletion of the loxP-ﬂanked region
by Cre-mediated recombination transfecting with a Cre-expressing
plasmid (Hovelmeyer et al., 2007) or with the His-TAT-NLS-Cre
fusion protein (Peitz et al., 2002). To detect recombination, the fol-
lowing primers were used, resulting in a 286-bp fragment: sen
50-TTGGATCACCATGCCAACTA-30, ase 50-TGCAGACCCGGAAA
TTAGAC-30. Finally, positive clones were injected into CB20 tetraploid
blastocysts to generate germline Smad7
ﬂ/+ mice. For detection of the
Smad7
ﬂ allele, the following primers were used, resulting in a 413 bp
fragment for wild-type and a 568 bp fragment for the Smad7
ﬂ allele:
sen 50-GTCAGGTTGGATCACCATGCC-30, ase 50-GACTGCCTGGA
GAAGTGTGTC-30.
Animals
Smad7
ﬂ/ﬂ, CD4-Cre (Lee et al., 2001) and CD2-Smad7 (Dominitzki
et al., 2007), all on C57BL/6 background, and wild-type C57BL/6
mice (Charles River) were kept in a speciﬁc pathogen-free barrier at
the central animal facilities of the Universities of Mainz and
Regensburg. All experiments were done in accordance with guidelines
of the Institutional Animal Care and Use Committees of the
Universities of Mainz and Regensburg.
Quantitative mRNA analysis
Total mRNA from magnetic-activated cell sorting (MACS)
TM (CD4
+,
CD8
+, CD19
+, CD90.2
+)- or FACSAria
TM-sorted mouse cells was iso-
lated using the TRIzol reagent (Invitrogen). Quantitative real-time
polymerase chain reaction (qRT–PCR) of mRNA coding for Foxp3,
GATA-3, IL-6, IL-10, IL-17A, IL-17F, plasminogen activator
inhibitor-1, Smad7, T-bet and TGF-b was performed using primers
from QIAGEN and the QuantiTect SYBR Green RT–PCR kit. qRT–
PCR of MACS
TM-isolated CD4
+ cells from patients with multiple
sclerosis or healthy donors was done using the following assay-
on-demand probes (Applied Biosystems): Smad7 (Hs00178696_m1)
and T-bet (Hs00203436_m1). The relative mRNA amounts were
determined by normalization to the glyceraldehyde 3-phosphate
dehydrogenase or 18S mRNA content. The expression levels of
mRNA were calculated using the CT method and normalized to
the wild-type control or human healthy donors.
Western blot
Proteins were isolated with radioimmunoprecipitation assay-buffer,
separated by sodium dodecyl sulfate polyacrylamide gel electrophor-
esis, transferred to nitrocellulose membranes and blocked with 5%
bovine serum albumin for 1h at room temperature. The following
primary monoclonal antibodies were used for overnight incubation:
Smad2 (L16D3; Cell Signaling), phosphorylated (p-)Smad2 (Ser465/
467) (138D4; Cell Signalling) and Actin (A2066; Sigma). Signals
were detected by Immobilon Western Chemiluminescent Horseradish
Peroxidase Substrate (Millipore) and Amersham Hyperﬁlm ECL (GE).
The relative amount of p-Smad2 was calculated by normalizing the
integrated density (volume of spot multiplied with the mean density)
of p-Smad2 on the integrated density of Actin.
Flow cytometry
Flow cytometry analyses were carried out with a FACSCalibur
TM ﬂow
cytometer (BD Biosciences). The following antibodies were purchased
from BD Biosciences unless otherwise speciﬁed: anti-mouse CD4
(L3T4), CD8a (clone 53-6.7), CD11b (clone M1/70), CD19 (clone
1D3), CD25 (clone 7D4), CD44 (clone IM7), CD45.2 (clone 104),
CD62L (clone MEL-14), CD69 (clone H1.2F3), CD90.2 (clone
53-2.1) and TCR-b (clone H57-597). Antibodies speciﬁc for mouse
IL-17A (clone TC11-18H10.1), IFN-g (clone XMG1.2) and Foxp3
(clone FJK-16s; eBioscience) were used for intracellular cytokine
staining.
T cell preparation and in vitro
differentiation
Naı ¨ve CD4
+CD62L
+ T cells were puriﬁed from spleens and lymph
nodes of at least two mice per genotype with magnetic-activated
cell sorting columns and magnetic beads (Miltenyi Biotec) as described
(Hovelmeyer et al., 2007) or with a FACSAria
TM ﬂuorescent cell sorter
(BD Biosciences). Purity of all cell preparations was measured by ﬂow
cytometry and was495%. Isolated and pooled T cells were stimulated
in complete (Kleiter et al., 2007) Roswell Park Memorial Institute
(RPMI) medium (Invitrogen) with soluble anti-CD3 (clone 145.2c11,
1mg/ml) and anti-CD28 (clone 37.51, 10ng/ml) for the indicated
times. To induce regulatory T cell polarization, TGF-b (0.4–2ng/ml)
was added, for Th1 IL-12 (10ng/ml) and anti-IL-4 (10mg/ml) and for
Th17 TGF-b (0.4–2ng/ml), IL-6 (20ng/ml), anti-IFN-g (10mg/ml) and
anti-IL-4 (10mg/ml). For some experiments serum-free X-Vivo 15
medium (Lonza) was used. All cytokines were bought from R&D
Systems and all antibodies were from BD Biosciences.
Induction and assessment of EAE
Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 (amino
acid sequence: MEVGWYRSPFSRVVHLYRNGK) (Mendel et al.,
1995) was obtained from Research Genetics. Active EAE was induced
in 6- to 8-week-old mice by immunization with 50mg of MOG(35–55)
peptide emulsiﬁed in complete Freund’s adjuvant (Difco Laboratories)
supplemented with 8mg/ml of heat-inactivated Mycobacterium tuber-
culosis H37RA (Difco Laboratories). The emulsion was administered as
a 100ml subcutaneous injection in the tail base. Mice received 200ng
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2days later. Weight and clinical score were recorded daily (0=healthy;
1=limp tail; 2=partial hindlimb weakness and/or ataxia; 3=complete
paralysis of at least one hindlimb; 4=severe forelimb weakness;
5=moribund or dead). EAE recovery was deﬁned as an improvement
of at least 1 scoring point for at least 2days.
Histological examination
Histology was performed as described (Prinz et al., 2008). Mice were
perfused during deep anaesthesia with ice-cold saline. Spinal cords
were removed and ﬁxed in 4% buffered formalin. Then, spinal cords
were dissected and embedded in parafﬁn before staining with haema-
toxylin and eosin, luxol fast blue to assess the degree of demyelina-
tion, macrophage-3 antigen (BD Pharmingen) for macrophages/
microglia, CD3 for T cells (Serotec), B220 for B cells (Serotec) and
deposition of amyloid precursour protein, which reﬂects axonal
damage.
Analysis of cells that inﬁltrate the CNS
Two weeks after immunization with MOG(35–55), mice were per-
fused with ice-cold phosphate buffered saline, brain and spinal cord
lysed with 2mg/ml collagenase, and inﬁltrating lymphocytes and res-
ident microglia were puriﬁed by percoll gradient (detailed protocol in
Greter et al., 2005). Cells were analysed by ﬂow cytometry either
immediately or after restimulation for 4h with 50ng/ml phorbol
12-myristate 13-acetate, 500ng/ml Ionomycin and 5mg/ml brefeldin
A. The proportion of CD45
highCD11b
low inﬁltrating lymphocytes
or CD45
highCD11b
high macrophages, respectively, versus CD45
dim
CD11b
dim resident microglia was used to calculate the number of
inﬁltrating cells.
T cell proliferation assay
Lymph node cells and splenocytes from MOG(35–55)-immunized mice
were stimulated with MOG peptide or Concanavalin (Con) A (Sigma)
in 200ml complete RPMI medium for 24–96h in 96-well round-bottom
culture plates (Kleiter et al., 2007). Cells were pulsed with 1mCi of
[3]H-thymidine (Amersham Biosciences) 16h before harvesting.
Incorporation of
[3]H-thymidine was measured by harvesting the cells
onto glass ﬁbre ﬁlters (Wallac Oy), followed by liquid scintillation
counting.
Enzyme linked immunosorbent assay
On day 14–16 after MOG immunization, mice were sacriﬁced and
splenocytes and lymphocytes from inguinal lymph nodes were dis-
sected. Isolated cells were restimulated with the indicated concentra-
tion of MOG peptide or ConA for 24–96h in complete RPMI medium.
Enzyme linked immunosorbent assay (ELISA) was performed according
to the manufacturer’s instructions to determine the cytokine concen-
trations of IFN-g, IL-4, IL-10, IL-17 (all BD Biosciences) and TGF-b
(R&D Systems) in the supernatants.
Material from patients with multiple
sclerosis and healthy donors
CD4
+ lymphocytes were isolated from the peripheral blood of patients
with relapsing–remitting multiple sclerosis diagnosed according to the
McDonald criteria (Polman et al., 2005) and age- and sex-matched
healthy donors. No patient had received immunosuppressive drugs or
disease-modifying agents at the time of blood analysis. They were free
of glucocorticosteroids for at least 2months. Patients were considered
in a stable disease course when no new neurological symptoms and no
MRI activity in the 6months before and 3months after the study were
found. Acute relapses were deﬁned as an episode of new neurological
symptoms lasting for at least 24h; and a blood sample was taken
within 4weeks after onset of relapse. All patients were examined
before glucocorticosteroid treatment. The study was approved by
the Ethics Committees of the Universities of Wu ¨rzburg (Study
Number 399, 11/06) and Regensburg (Study Number 06/164), and
informed consent was obtained from all subjects.
Statistical analysis
All experiments were analysed by ANOVA on ranks, followed by
pair-wise multiple comparison procedures to identify groups that
were different. A value of P50.05 was considered statistically signif-
icant. For comparison of human Smad7- and T-bet-expression
Spearman’s rank correlation was used. All statistical tests were per-
formed with SigmaStat 3.0 software (SPSS Inc.).
Results
Generation of mice with a speciﬁc
deletion of Smad7 in T cells
Smad7 is an intracellular inhibitor of TGF-b receptor signalling.
Following reports indicating that TGF-b signalling plays a critical
role in T cell differentiation, we were interested to investigate if
the expression level of Smad7 regulates these processes. A pre-
viously reported Smad7 knockout mouse expresses a truncated
Smad7 protein and exhibits a reduced birth rate (Li et al.,
2006b). We therefore reasoned that complete Smad7-deﬁciency
would lead to embryonic lethality and opted to use the Cre/loxP
system to delete Smad7 in a cell-type speciﬁc manner. We con-
structed a targeting vector to ﬂank a 3.4kb fragment that con-
tained the promoter and exon I of the smad7 gene with loxP sites
(Supplementary Fig. 1A). This targeting vector was used to trans-
fect embryonic stem cells of C57BL/6 origin (Kontgen et al.,
1993). Homologous recombinant stem cell clones were tested
for speciﬁc deletion of the loxP-ﬂanked allele (Supplementary
Fig. 1B) and used for blastocyst injection. Germline transmission
was veriﬁed by Southern blot and PCR analysis (Supplementary
Fig. 1C). After removal of the neomycin resistance cassette by
Flp-mediated recombination (Rodriguez et al., 2000), mutant
Smad7
ﬂ/+ mice were crossed to mice that express the
Cre-recombinase early in embryogenesis (Schwenk et al., 1995).
The offspring, Smad7
/+ mice, were intercrossed; of 45 mice born,
29 were heterozygous for Smad7 deletion, 16 were wild-type
(giving a ratio of 1.8:1), and none were homozygous, demonstrat-
ing that deletion of Smad7 leads to embryonic lethality.
Next, Smad7
ﬂ/ﬂ mice were crossed to mice carrying the
CD4Cre allele (Lee et al., 2001), resulting in CD4Cre-Smad7
ﬂ/ﬂ
mice with speciﬁc deletion of the targeted allele in CD4
+ cells
(Supplementary Fig. 1D). Smad7
ﬂ/ﬂ and CD4Cre-Smad7
ﬂ/ﬂ mice
1070 | Brain 2010: 133; 1067–1081 I. Kleiter et al.were born at the expected Mendelian frequencies and survived
normally under pathogen-free conditions. qRT–PCR showed the
deletion of Smad7-mRNA in puriﬁed CD4
+, CD8
+ and CD90.2
+
cells but not in CD19
+ B lymphocytes, CD11b
+ myeloid cells or
CD11c
+ dendritic cells (Fig. 1A, Supplementary Fig. 2A and B). In
addition, recombination could be excluded in CD19
+ B lympho-
cytes and CD11c
+ dendritic cells (Supplementary Fig. 2C), alto-
gether demonstrating a T cell-speciﬁc deletion of Smad7. The
TGF-b1-induced increase of Smad7-mRNA was abolished in
CD4
+ cells lacking Smad7 (Fig. 1B), and expression of TGF-b1
downstream-signalling molecules such as phosphorylated Smad2
and plasminogen activator inhibitor-1 was enhanced (Fig. 1C–E).
As a negative control we used T cells with a CD2-restricted Smad7
over-expression (CD2-Smad7 strain) (Dominitzki et al., 2007).
Distribution of lymphocyte populations
in CD4Cre-Smad7
ﬂ/ﬂ mice
To investigate whether deletion of Smad7 in T cells affects the
homeostasis of T and B cell populations, we analysed naı ¨ve
CD4Cre-Smad7
ﬂ/ﬂ mice and littermate controls. In the thymus,
the frequencies of CD4
+ and CD8
+ single positive as well
as CD4
+CD8
+ double positive cells were unaltered (Fig. 2A,
Supplementary Table 1). No differences were found in total num-
bers and ratios of CD4
+/CD8
+ cells and B/T cells in the spleen
(Fig. 2B, Supplementary Table 2) as well as in lymph nodes
(data not shown). Although the proportion of naı ¨ve
CD4
+CD44
lowCD62L
high T cells, and of T cells with a memory
phenotype (CD4
+CD44
highCD62L
low) was unchanged, we
observed a small, but signiﬁcant, decrease of CD4
+ and CD8
+
cell frequencies with an activated phenotype (CD69
high) in periph-
eral lymphoid organs from mice where Smad7 was deleted in
T cells (Fig. 2C, Supplementary Table 2).
To test whether the deletion of Smad7 affects the steady state
of regulatory T cell populations, we analysed the proportion
of CD4
+CD25
+Foxp3
+ cells from the thymus and spleen.
We found no differences in the frequencies of regulatory T cells
in CD4Cre-Smad7
ﬂ/ﬂ mice compared to controls (Fig. 2D,
Supplementary Table 2). In summary, apart from a signiﬁcant
decrease in the number of activated T cells in the periphery, the
lack of Smad7 in T cells did not affect the distribution of thymic or
peripheral lymphocyte subsets in antigen-unchallenged mice.
Altered T cell differentiation in
Smad7-deﬁcient T cells
To determine whether the expression level of Smad7 affects T cell
differentiation, we examined the generation of T cell subsets in the
presence of polarizing cytokines and anti-CD3/CD28 stimulation
in vitro. We found that Th1 differentiation was reduced in T cells
from CD4Cre-Smad7
ﬂ/ﬂ mice and enhanced in T cells from
CD2-Smad7 mice (Fig. 3A and B). The Th1-speciﬁc transcription
Figure 1 CD4Cre-Smad7
ﬂ/ﬂ mice show a CD4
+ cell-speciﬁc deletion of Smad7 and enhancement of TGF-b downstream signalling.
(A–C) qRT–PCR analysis of Smad7- and plasminogen activator inhibitor (PAI)-1 mRNA in puriﬁed lymphocytes from naı ¨ve mice (n=3).
Expression is presented relative to 18S-RNA and normalized on wild-type CD4
+ cells (=1.0 arbitrary units). (B and C) CD4
+ cells were
stimulated with 2ng/ml TGF-b1 for 4h. CD4
+ cells over-expressing Smad7 (CD2-Smad7) were used as control. (D and E) Western
blot of puriﬁed CD4
+ cells, stimulated with 2ng/ml TGF-b1 for the indicated time. TGF-b downstream signalling is absent in
Smad7-over-expressing and enhanced in Smad7-deﬁcient CD4
+ cells. (E) Densitometry of phosphorylated (p-)Smad2 relative to Actin
(n=3), normalized on wild-type CD4
+ cells stimulated for 30min with TGF-b1 (=1.0 arbitrary units). (A–C, E) Bars show mean SEM of at
least two independent experiments.  P50.05,    P50.001 (ANOVA).
Smad7 drives Th1 responses in MS and EAE Brain 2010: 133; 1067–1081 | 1071Figure 2 Distribution of central and peripheral T cell populations in CD4Cre-Smad7
ﬂ/ﬂ mice. Flow cytometry of thymocytes, splenocytes
and lymphocytes obtained from 8-week-old CD4Cre-Smad7
ﬂ/ﬂ mice and littermate controls, stained with the indicated antibodies. (A)
Analysis of CD4
+/CD8
+ ratio from the thymus. (B) Analysis of CD4
+/CD8
+ ratio and T (CD90.2
+)/B (CD19
+) cell ratio from the spleen. (C)
Proportion of naı ¨ve (CD69
low) versus activated (CD69
high) CD4
+ and CD8
+ cells from lymph nodes. (D) Analysis of CD25
+Foxp3
+
regulatory T cells from thymus and spleen. In all graphs, data are representative of two independent experiments with at least three mice
per genotype. Data are shown for cells in the thymocyte/lymphocyte gate only (A and B), or further gated on CD4
+ or CD8
+ (C and D).
Dead cells were excluded using Topro3. Numbers in the graphs indicate the percentage of cells from the gated population.
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even after addition of TGF-b1. Thus, Th1 effector cells with high
Smad7 levels were less prone to suppression by TGF-b1, as shown
by elevated IFN-g expression. In contrast, T cells lacking Smad7
showed a signiﬁcantly enhanced suppression of T-bet- and
IFN-g-mRNA after TGF-b1-stimulation compared to Smad7
over-expressing T cells. During Th17 differentiation, which
depends on the cytokines IL-6 and TGF-b (Veldhoen et al.,
2006), Smad7-deﬁcient T cells produced more IL-17A compared
to wild-type T cells, while Smad7 over-expressing T cells produced
less. Similar observations were made for mRNA expression of
IL-17A and of the speciﬁc transcription factor RORgt. Next, we
examined differentiation of induced regulatory T cells and found
an increased expression of the speciﬁc transcription factor FoxP3
Figure 3 Smad7-deﬁciency increases TGF-b responses during in vitro T cell differentiation. Naı ¨ve CD4
+CD62L
+ T cells were obtained
from 8-week-old wild-type (WT), CD4Cre-Smad7
ﬂ/ﬂ and CD2-Smad7 mice. (A) T cells were incubated under Th1, Th17 and regulatory
T cell (Treg) differentiation conditions for 5days and stained with the indicated antibodies. Before staining for IL-17A and IFN-g, cells were
triggered with phorbol 12-myristate 13-acetate/Ionomycin and golgi stop for 4h. Data are shown for cells gated on CD4
+ lymphocytes,
excluding dead cells using Topro3. Numbers in the graphs indicate the percentage of cells from the gated population. One representative
example of three to ﬁve independent experiments is shown. (B) qRT–PCR of transcription factors and cytokines speciﬁc for Th1, Th17 and
regulatory T cell lineage polarization. Naı ¨ve T cells were puriﬁed and incubated for 5days under differentiation conditions with or without
2ng/ml TGF-b1( n=2–3). Shown is the expression relative to 18S-RNA. (C) ELISA measuring IL-10 secretion of T cells after stimulation in
Th17 polarizing conditions for 5days (n=5). (D) ELISA measuring TGF-b1 secretion (n=3). Puriﬁed CD4
+ cells were stimulated in
serum-free medium with anti-CD3/CD28 and IL-2 (10ng/ml) for 72h. (E) qRT–PCR showing a time kinetic of Smad7, speciﬁc
transcription factors and cytokines during Th1 and Th17 differentiation of wild-type T cells (n=3). Expression is presented relative to
18S-RNA and normalized on the unstimulated control (=1.0 arbitrary units). (B–E) Bars show mean SEM of independent experiments.
 P50.05 (ANOVA).
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in Smad7-over-expressing T cells. Since sustained TGF-b stimula-
tion drives IL-10 production in Th17 cells (McGeachy et al., 2007),
we also examined IL-10 secretion by Th17 differentiated T cells.
Although considerable amounts of IL-10 were secreted with a
rising TGF-b concentration, no signiﬁcant difference was found
in Smad7-deﬁcient T cells compared to wild-type T cells, but
Smad7-over-expressing T cells secreted less IL-10 (Fig. 3C).
Secretion of IL-9 was below detection limit in Smad7-deﬁcient
and over-expressing T cells during Th17 differentiation (data not
shown).
To investigate whether TGF-b produced by the T cells contrib-
uted to the changes in T cell differentiation, we stimulated puriﬁed
T cells with anti-CD3/CD28 and IL-2 under serum-free conditions
and measured TGF-b1 secretion by ELISA. Indeed, T cells from
CD4Cre-Smad7
ﬂ/ﬂ mice produced signiﬁcantly higher levels of
TGF-b1 than T cells from CD2-Smad7 mice and thus could poten-
tially serve as a source of TGF-b (Fig. 3D).
Finally, we tested the hypothesis that Smad7-expression is
altered during T cell differentiation to enhance or inhibit polariza-
tion under the control of TGF-b. It has been shown before that
inducible regulatory T cells down-regulate Smad7 by
FoxP3-mediated inhibition of Smad7 promoter activity (Fantini
et al., 2004). We found a signiﬁcant reduction of Smad7-mRNA
expression during Th17 differentiation of wild-type T cells and an
increase during Th1 differentiation (Fig. 3E). Interestingly, the
change in the expression of Smad7 preceded up-regulation of
the lineage-speciﬁc transcription factor and effector cytokine in
Th17, but not in Th1 polarization.
Decreased EAE in CD4Cre-Smad7
ﬂ/ﬂ
mice
Th1, Th17 and regulatory T cells were shown to play important
roles in autoimmune brain inﬂammation (McFarland and Martin,
2007). To test if deletion of Smad7 affects inﬂammation in vivo,
we immunized CD4Cre-Smad7
ﬂ/ﬂ mice as well as Smad7
ﬂ/+,
Smad7
ﬂ/ﬂ and CD4Cre-Smad7
ﬂ/+ littermate controls with the
MOG 35–55 peptide and examined disease progression by clinical
evaluation. The incidence of EAE was reduced by  40% in
CD4Cre-Smad7
ﬂ/ﬂ mice (Fig. 4A, Table 1). Signs of paralysis in
sick CD4Cre-Smad7
ﬂ/ﬂ mice started slightly earlier as compared
to control animals, indicating that early events in EAE pathogen-
esis, such as recruitment of inﬂammatory cells, might be enhanced
in the absence of Smad7 expression in Tcells. However,
CD4Cre-Smad7
ﬂ/ﬂ mice did not develop severe EAE, but rather
milder clinical signs of the disease. Furthermore, most diseased
animals in that group recovered earlier than control mice (after
5.4 1.02 SD days).
To investigate T cell proliferation, we isolated T cells of
CD4Cre-Smad7
ﬂ/ﬂ mice and littermate controls 15 days after
immunization with MOG(35–55). Upon restimulation with
MOG-peptide, Smad7-deﬁcient T cells proliferated signiﬁcantly
less than control T cells (Fig. 4B). Smad7-deﬁcient T cells also
proliferated less when stimulated with Concanavalin A.
Next, we analysed histological samples from brain and spinal
cord tissue obtained 28 days after induction of EAE. In correlation
with the clinical disease scores, we found less inﬂammation,
demyelination and axonal damage in CD4Cre-Smad7
ﬂ/fl mice as
compared to control mice (Fig. 4C). Detailed analysis revealed
reduced numbers of inﬁltrating mononuclear cells such as invading
CD3
+ T cells, macrophage-3 antigen
+ macrophages/microglia and
B220
+ B cells (Fig. 4D). Furthermore, demyelination and deposi-
tion of amyloid precursor protein, a marker for axonal damage,
were reduced.
Th1 responses are reciprocally altered
during EAE in mice with T cell-speciﬁc
deletion and over-expression of Smad7
To conﬁrm our in vivo data indicating that Smad7 expression in
T cells contributes to the development of EAE, we used a second
mouse model with T cell-speciﬁc over-expression of Smad7. After
immunization with MOG(35–55), CD2-Smad7 mice showed a
normal onset of disease at Day 10, illustrating that the priming
phase of EAE was unaltered (Fig. 5A, Table 1). The clinical course
of EAE in CD2-Smad7 mice inversely correlated with
CD4Cre-Smad7
ﬂ/ﬂ mice and disease was more severe compared
to wild-type mice, with a signiﬁcantly increased mean maximum
disease score and a mortality of 30% occurring 4.3 0.47days
after onset of disease. Prior to death, CD2-Smad7 mice showed
typical EAE with progressive ascending paralysis but no clinical
signs of an exaggerated systemic inﬂammatory response. In con-
trast to CD4Cre-Smad7
ﬂ/ﬂ mice, the proliferation of splenocytes
obtained from CD2-Smad7 mice was not altered compared to
wild-type controls (Supplementary Fig. 3A).
To investigate the phenotype and migration of activated T cells
to the CNS during EAE, we isolated CNS inﬁltrating cells of mice
15days after immunization with MOG(35–55). In accordance
with an ameliorated clinical disease score in CD4Cre-Smad7
ﬂ/ﬂ
mice, there was a signiﬁcant reduction in the number of inﬁltrating
CD45
highCD11b
low total lymphocytes and CD4
+CD45
highCD11b
low
T cells versus CD45
dimCD11b
dim CNS-resident cells compared to
wild-type controls (Fig. 5B and C). In contrast, CD2-Smad7 mice
showed signiﬁcantly enhanced numbers of inﬁltrating total lym-
phocytes and CD4
+ T cells during acute EAE compared to
CD4Cre-Smad7
ﬂ/ﬂ mice. Whereas the frequencies of inﬂammatory
Th1 and Th17 cells in CD4Cre-Smad7
ﬂ/ﬂ mice were slightly lower
compared to wild-type controls at Day 15 after immunization,
CD2-Smad7 mice showed a signiﬁcant increase of Th1 cells and
a trend towards less Th17 cells in the inﬂamed CNS (Fig. 5B and
D). Finally, numbers of inﬁltrating regulatory T cells in the CNS
were reduced in CD2-Smad7 mice and increased in
CD4Cre-Smad7
ﬂ/ﬂ mice.
Next, we investigated whether during antigen restimulation
cytokine secretion and T cell differentiation were differentially
regulated in the experimental groups. Interestingly, we found
an inverse correlation of Th1- and Th17-inhibition in
Smad7-deﬁcient versus over-expressing T cells (Fig. 5E and F).
Whereas CD4Cre-Smad7
ﬂ/ﬂ splenocytes secreted signiﬁcantly
less IFN-g, CD2-Smad7 splenocytes secreted less IL-17A
1074 | Brain 2010: 133; 1067–1081 I. Kleiter et al.Figure 4 Reduced EAE in mice with a T cell-speciﬁc deletion of Smad7. (A) Clinical scores of MOG(33–55)-induced EAE for mice (n=5)
with a T cell-speciﬁc Smad7 deletion (CD4Cre-Smad7
ﬂ/ﬂ) and littermate controls (Smad7
ﬂ/ﬂ, Smad7
ﬂ/+). The difference in mean clinical
scores for the CD4Cre-Smad7
ﬂ/ﬂ and the control groups was statistically signiﬁcant from Day 14 to 27 (P50.05, ANOVA). Results are
presented as mean values SEM and are representative of two different experiments. (B) Proliferation assay of splenocytes obtained at
Day 15 after immunization and restimulated with increasing concentrations of MOG(35–55) (left) or Con A (right) for 96h. Proliferation
was measured by thymidine-incorporation. Data are expressed as the mean SEM of three independent experiments.  P50.05;
  P50.005 compared to Smad7
ﬂ/+ (ANOVA). (C) Immunohistochemistry of parafﬁn-embedded spinal cord sections from
paraformaldehyde-perfused Smad7
ﬂ/+, Smad7
ﬂ/ﬂ and CD4Cre-Smad7
ﬂ/ﬂ mice on Day 28 after induction of EAE with MOG(35–55).
Sections were stained with haematoxylin and eosin, luxol fast blue-periodic acid Schiff (LFB), anti-macrophage-3 antigen (Mac-3),
anti-CD3, anti-B220 or anti-amyloid precursor protein to visualize axonal damage. Shown are sections of representative mice. Arrows
indicate positive cells. Scale bar 100mM. (D) Summary of experiment shown in (C), the horizontal line represents the mean of all mice per
group. ANOVA was used for statistical analysis;  P50.05 (Smad7
ﬂ/+ versus CD4Cre-Smad7
ﬂ/ﬂ).
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IFN-g secretion by Smad7-over-expressing T cells after 24h resti-
mulation with anti-CD3/CD28, consistent with a decrease
of IFN-g produced by Smad7-deﬁcient T cells (Fig. 5G).
Splenocytes obtained from CD4Cre-Smad7
ﬂ/ﬂ and CD2-Smad7
mice did not secrete IL-4 (data not shown) and only low
amounts of IL-10 (Supplementary Fig. 3B) during antigen
restimulation.
To analyse T cell differentiation further during EAE in these
mice, we performed qRT–PCR analysis of RNA extracted from
peripheral CD4
+ cells obtained at the peak of acute disease
(Fig. 5H). Whereas transcripts for the Th1 transcription factor
T-bet were up-regulated in CD2-Smad7 mice, no major changes
were observed for transcription factors of the Th2 (GATA3) and
regulatory T cell (FoxP3) lineages in CD4Cre-Smad7
ﬂ/ﬂ and
CD2-Smad7 mice. Th17-speciﬁc transcripts (IL-17A, IL-17F) were
up-regulated in CD4
+ cells of CD4Cre-Smad7
ﬂ/ﬂ mice and
down-regulated in CD2-Smad7 mice. Notably, mRNA coding for
IL-10, whose expression is increased in Th17 cells with a regula-
tory phenotype (McGeachy et al., 2007), was also up-regulated in
CD4
+ cells lacking Smad7. Thus, similar to in vitro differentiation,
during EAE and upon antigen restimulation CD4
+ cells lacking
Smad7 differentiated less, and CD4
+ cells with Smad7
over-expression differentiated more to a Th1 phenotype, whereas
Th17 differentiation was reciprocally altered.
To test if peripheral T cell populations, in particular regulatory
T cells, were altered after EAE induction in CD4Cre-Smad7 mice,
we examined the distribution of T cell subpopulations in the spleen
and draining lymph nodes 14 days after immunization with
MOG(35–55). The total T cell numbers as well as the ratio of
CD4
+/CD8
+ cells and naı ¨ve (CD4
+CD44
lowCD62L
high) versus
memory (CD4
+CD44
highCD62L
low) T cells did not differ between
CD4Cre-Smad7
ﬂ/ﬂ and control mice (Supplementary Fig. 3C and
D). Moreover, no change in the number of peripheral regulatory T
cells was found in CD4Cre-Smad7
ﬂ/ﬂ and CD2-Smad7 mice
(Supplementary Fig. 3E).
Smad7 is up-regulated in CD4
+ T cells
during active multiple sclerosis and
correlates with T-bet
To test whether over-expression of Smad7 in peripheral lympho-
cytes contributes to human autoimmune CNS inﬂammation as
seen in CD2-Smad7 mice, we isolated CD4
+ cells from patients
with relapsing remitting multiple sclerosis (Supplementary Table 3)
during relapse (n=16) and analysed Smad7-mRNA expression by
qRT–PCR. Indeed, we found a signiﬁcant increase of Smad7
expression during active multiple sclerosis, but not during remis-
sion (n=15) or in healthy controls (n=15) (Fig. 6A). Furthermore,
there was a high correlation (R=0.81) of Smad7 expression with
expression of the Th1-speciﬁc transcription factor T-bet (Fig. 6B),
suggesting that during relapses of multiple sclerosis TGF-b signal-
ling in peripheral CD4
+ cells is inhibited and hence a Th1 response
predominates.
Discussion
In this work, we have investigated how an intracellular signalling
inhibitor of TGF-b regulates T cell differentiation in vitro, during
EAE and in patients with multiple sclerosis. We found a signiﬁ-
cantly increased expression level of Smad7 in CD4
+ cells from
patients with acute relapses as compared to remission and healthy
controls. Furthermore, expression of Smad7 highly correlated with
that of T-bet, a transcription factor deﬁning Th1 responses (Szabo
et al., 2000). Using mutant mice we demonstrate that the expres-
sion level of Smad7 in T cells dictates whether a Th1 or a Th17
response evolves during T cell differentiation in vitro and after
immunization of mice with an encephalitogenic peptide. Since
susceptibility to EAE was associated with elevated Smad7 and a
predominant Th1, but not Th17 polarization, we propose that
both initiation of EAE and relapses in multiple sclerosis are
mainly T-bet-/Th1-driven.
After characterization of IL-17 producing effector T cells, it was
suggested that Th17 are the main pathogenic population causing
EAE (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al.,
2006). By showing that CD4Cre-Smad7
ﬂ/ﬂ mice have mild disease
despite a normal peripheral Th17 response and CD2-Smad7 mice
have severe disease despite a decrease of Th17 differentiation in
the periphery and the CNS, we demonstrate that a Th1 response is
not only sufﬁcient, but necessary to induce EAE, and present fur-
ther evidence that IL-17 producing cells are dispensable for EAE
induction (Haak et al., 2009). As a note of caution,
Smad7-deﬁcient Th17 cells may be phenotypically or functionally
different from wild-type Th17 cells.
Recent reports suggested that organ-speciﬁc autoimmune
inﬂammation can be induced by both, polarized Th17 as well as
Table 1 Clinical features of MOG(35–55)-induced EAE
Genotype Incidence EAE-related deaths Day of onset Maximum clinical score
Smad7
ﬂ/+ 26 of 26 (100%) 0 of 26 11.19 2.27 3.17 0.80
Smad7
ﬂ/ﬂ 37 of 41 (90.2%) 0 of 41 12.11 2.26 2.56 1.26
CD4Cre-Smad7
ﬂ/+ 8 of 8 (100%) 0 of 8 10.75 1.56 3.00 0.61
CD4Cre-Smad7
ﬂ/ﬂ 19 of 34 (55.9%) 0 of 34 9.79 1.96  1.25 1.32   
CD2-Smad7 10 of 10 (100%) 3 of 10 10.60 1.43 4.25 0.64
§
Smad7
ﬂ/ﬂ, CD4Cre-Smad7
ﬂ/+, Smad7
ﬂ/+ indicate the control mice (no homozygous Cre-mediated deletion of Smad7), CD2-Smad7 the Smad7-over-expressing control.
Results are presented as mean SD and show the total number of individual mice within two (CD4Cre-Smad7
ﬂ/+, CD2-Smad7), ﬁve (Smad7
ﬂ/+), or seven (Smad7
ﬂ/ﬂ,
CD4Cre-Smad7
ﬂ/ﬂ) independent experiments. ANOVA was used for statistical analysis.  P50.05 compared to Smad7
ﬂ/+ and Smad7
ﬂ/ﬂ,    P50.001 compared to all other
genotypes,
§P50.001 compared to Smad7
ﬂ/+, Smad7
ﬂ/ﬂ and CD4Cre-Smad7
ﬂ/ﬂ.
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antigen exposure determine the effector phenotype (Kroenke
et al., 2008; Luger et al., 2008; Steinman, 2008). However, it
was demonstrated that only Th1 cell lines can consistently
induce EAE and that the encephalitogenicity of Th17 cells depends
on activation of the transcription factor T-bet (Yang et al., 2009).
Accordingly, T-bet deﬁcient mice are resistant to various allergic
and autoimmune diseases, including EAE (Nath et al., 2006).
We have shown that during in vitro differentiation and in the
course of EAE Smad7-expression regulates the generation of Th1
cells, which are known to express high levels of Smad7 (Veldhoen
et al., 2006). Smad7 may be an early marker of Th1 polarization,
since both Smad7 (Ulloa et al., 1999) and T-bet (Afkarian et al.,
2002) are activated by the transcription factor signal transducer
and activator of transcription (STAT)-1. It has been shown that
proinﬂammatory cytokines like IFN-g and TNF- up-regulate
Smad7 through STAT1, which allows a Th1 response to proceed
without suppression by TGF-b (Ulloa et al., 1999; Bitzer et al.,
2000). Indeed, lymphocytes up-regulate Smad7 during antigen
restimulation and inhibition of Smad7 by speciﬁc antisense oligo-
nucleotides reduces T cell proliferation, the clinical score and neu-
roinﬂammation during EAE (Kleiter et al., 2007). Our data conﬁrm
that Smad7 is a critical factor in the generation of Th1 cells, but it
remains to be determined if Smad7 interacts with or regulates
signalling pathways or transcription factors involved in Th1
differentiation.
It was shown that Smad7 expression is absent in T cells from
multiple sclerosis patients with a stable disease course and increase
in the frequency of peripheral regulatory T cells (Correale and
Farez, 2007). Contrary to Th1 cells, regulatory T cells
down-regulate Smad7-mRNA (Mizobuchi et al., 2003; Fantini
et al., 2004). The proinﬂammatory cytokine IL-6 blocks regulatory
T cell generation by transactivation of Smad7-mRNA and
CD4
+CD25
  T cells from CD2-Smad7 mice are resistant to the
induction of Foxp3 (Dominitzki et al., 2007). We found that
Foxp3 expression was enhanced under in vitro conditions in
Smad7-deﬁcient and reduced in Smad7-over-expressing T cells.
In vivo, we found the number of CNS inﬁltrating regulatory
T cells to be reduced in CD2-Smad7 compared to CD4Cre-
Smad7
ﬂ/ﬂ mice. In contrast, regulatory T cell frequencies in the
periphery were unaltered. Enhanced frequencies of regulatory T
cells in the CNS may have contributed to the reduction of total
lymphocytes as well as Th1 and Th17 effector T cells in the CNS
of CD4Cre-Smad7
ﬂ/ﬂ mice.
TGF-b controls T cell homeostasis at multiple checkpoints
including T cell activation, proliferation, differentiation and apop-
tosis (Li et al., 2006a). Many immune cells are responsive to
TGF-b (Letterio and Roberts, 1998), but it is now apparent that,
in particular, the loss of TGF-b signalling in T cells results in the
breakdown of tolerance and autoimmunity. Contrary to mice with
TGF-bR-deﬁciency in T cells, which show T cell activation, expan-
sion of autoreactive T cells and reduced peripheral numbers of
regulatory T cells (Li et al., 2006c; Marie et al., 2006), mice lack-
ing Smad7 in T cells exhibited a normal distribution of peripheral
T cell subsets and a reduction in CD69
+ activated T cells.
Smad7-deﬁcient T cells proliferated less during antigen-speciﬁc
and polyclonal restimulation. Although it is highly likely that also
in vivo Smad7-deﬁcient T cells proliferate less in situations where
TGF-b is present, a T cell intrinsic defect or compromised antigen
presentation could have added to reduced T cell activation in
CD4Cre-Smad7
ﬂ/ﬂ mice. We did, however, exclude a deletion of
Smad7 in antigen presenting cells as a confounding factor.
Interestingly, Smad7-deﬁcient T cells produced more TGF-b
upon anti-CD3/28 stimulation compared to controls, which may
have enhanced the inhibitory effects on Th1 differentiation, acting
through auto- or paracrine mechanisms. Finally, it is conceivable
that deletion of Smad7 also rendered CD8
+ T cells more suscep-
tible to the effects of TGF-b, which could have altered their effec-
tor functions (Li et al., 2006a). Thus, insufﬁcient T cell activation
as well as tolerance induction through TGF-b may have contrib-
uted to the decreased autoimmune neuroinﬂammation in
CD4Cre-Smad7
ﬂ/ﬂ mice.
We demonstrate up-regulation of Smad7-mRNA in T cells of
patients with active multiple sclerosis, which highly correlated
with the expression of T-bet. Similar to CD2-Smad7 mice, a pre-
dominance of Th1 responses in the periphery during multiple scle-
rosis relapses is likely. Indeed, in patients with relapsing-remitting
multiple sclerosis increased expression of pSTAT1 and T-bet in
peripheral CD4
+ and CD8
+ cells was shown to correlate with clin-
ical and magnetic resonance imaging activity (Frisullo et al., 2006)
as well as expression of T-bet in peripheral blood mononuclear
cells with response to interferon-beta treatment (Drulovic et al.,
2009). Enhanced type I interferon responses in the serum have
been reported in a subset of patients with multiple sclerosis (Degre
et al., 1976; van Baarsen et al., 2006; Comabella et al., 2009) and
in subjects with other inﬂammatory diseases like Sjo ¨gren’s syn-
drome (Emamian et al., 2009), rheumatoid arthritis (van der
Pouw Kraan et al., 2007) and systemic lupus erythematosus
(Baechler et al., 2003), and may be a general mechanism of auto-
immunity. Notably, the IRF8 locus, which is involved in the regu-
lation of responses to type I interferons, was recently identiﬁed as
a new susceptibility allele for multiple sclerosis (De Jager et al.,
2009).
Others have found that both Th1 and Th17 responses are ele-
vated in peripheral CD4
+ cells during relapses (Fransson et al.,
2009; Kebir et al., 2009), leaving the possibility that either
Smad7 is over-expressed only in a subset of CD4
+ cells, that
Smad7 expression in peripheral CD4
+ cells is transient, or that
CD4
+ cells secreting both IFN-g and IL-17 are generated in the
presence of elevated Smad7 expression. Interestingly, mononuc-
lear cells in the cerebrospinal ﬂuid from patients with multiple
sclerosis show elevated IL-17 mRNA expression and a relative
increase of IL-17 expressing cells compared to blood
(Matusevicius et al., 1999; Brucklacher-Waldert et al., 2009).
Furthermore, signiﬁcant numbers of perivascular dendritic cells
capable of driving Th17 differentiation and of intralesional IL-17
producing CD4
+ cells were found in patients with multiple sclerosis
(Ifergan et al., 2008; Tzartos et al., 2008). Hence, unlike the
situation in the periphery, Th17 cells may be the predominant
effector T cell population in the CNS of patients with multiple
sclerosis. Finally, multiple sclerosis lesions show a gene expression
proﬁle of IL-6, IL-17, osteopontin and of IFN-driven transcriptional
activity (Chabas et al., 2001; Lock et al., 2002).
Smad7 drives Th1 responses in MS and EAE Brain 2010: 133; 1067–1081 | 1077Figure 5 Reciprocally altered Th1 and Th17 responses during EAE in mice with T cell-speciﬁc deletion and over-expression of Smad7.
(A) Clinical scores of MOG(33-55)-induced EAE for mice (n=10) with a T cell-speciﬁc Smad7 deletion (CD4Cre-Smad7
ﬂ/ﬂ), littermate
controls (Smad7
ﬂ/+) or a T cell-speciﬁc over-expression of Smad7 (CD2-Smad7). The difference in clinical scores for CD4Cre-Smad7
ﬂ/ﬂ
versus CD2-Smad7 mice was statistically signiﬁcant from Day 12 to 16 (P50.001, ANOVA). Results are presented as mean values SEM.
Pooled mice from two experiments are shown. (B) Mice were immunized with MOG(35–55) and CNS inﬁltrating cells isolated at Day 15.
The ﬁrst panel shows the number of CD45.2
highCD11b
low inﬁltrating lymphocytes (R1) and CD45.2
highCD11b
high inﬁltrating macrophages
Continued
1078 | Brain 2010: 133; 1067–1081 I. Kleiter et al.In summary, we have shown that Smad7, which is critically
involved in TGF-b signalling, is a major regulator of T cell differ-
entiation and autoimmune CNS inﬂammation that governs the
Th1/Th17 decision. Increased Smad7 expression in CD4
+ cells
was found during active multiple sclerosis and aggravated clinical
disease and Th1 responses in the EAE model. Lack of Smad7 in T
cells ameliorated EAE and blunted Th1 effector mechanisms.
Targeting of Smad7 might therefore be a valuable therapeutic
approach for T cell-mediated autoimmune diseases of the CNS.
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